This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cao, J. Articles by Blair, W. S. Search for Related Content PubMed PubMed Citation Articles by Cao, J. Articles by Blair, W. S.

High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full Replication Assay That Includes HIV-1 Vif as an Antiviral Target

Department of Virology, Pfizer Global Research and Development, La Jolla Laboratories, 10777 Science Center Dr. (CB1), San Diego, California 92121

Received 3 March 2005/ Returned for modification 28 April 2005/ Accepted 26 May 2005

Antiviral screens have proved useful for the identification of novel human immunodeficiency virus type 1 (HIV-1) inhibitors. In this study, we describe an HIV-1 full replication (HIV-1 Rep) assay that incorporates all of the targets required for replication in T-cell lines, including the HIV-1 Vif gene. The HIV-1 Rep assay was designed to exhibit optimal sensitivity to late-stage as well as early-stage inhibitors to maximize the likelihood of identification of novel target antiviral compounds in a screen. In addition, the flexibility of the HIV-1 Rep assay allows the rapid evaluation of antiviral compounds against different virus strains in different T-cell lines without significant modification of the assay format. We demonstrate that the HIV-1 Rep assay exhibits characteristics (e.g., a favorable Z' value) compatible with high-throughput screening in a 384-well format. The utility of the HIV-1 Rep assay was demonstrated in a high-throughput screen of >10⁶ compounds. To our knowledge, this study represents the first example of an HIV-1 antiviral screen that includes Vif as a functional target and was executed on an industrial scale.

This article has been cited by other articles:

• Blair, W. S., Cao, J., Jackson, L., Jimenez, J., Peng, Q., Wu, H., Isaacson, J., Butler, S. L., Chu, A., Graham, J., Malfait, A.-M., Tortorella, M., Patick, A. K. (2007). Identification and Characterization of UK-201844, a Novel Inhibitor That Interferes with Human Immunodeficiency Virus Type 1 gp160 Processing. Antimicrob. Agents Chemother. 51: 3554-3561 [Abstract] [Full Text]  
• Hallis, T. M., Kopp, A. L., Gibson, J., Lebakken, C. S., Hancock, M., Vandenheuvel-Kramer, K., Turek-Etienne, T. (2007). An Improved {beta}-Lactamase Reporter Assay: Multiplexing with a Cytotoxicity Readout for Enhanced Accuracy of Hit Identification. J Biomol Screen 12: 635-644 [Abstract]